Regulation of prostaglandin EP1 and EP4 receptor signaling by carrier-mediated ligand reuptake

Pharmacology Research and Perspectives

Volumn 2, Issue 5, 2014, Pages

  Chi, Yuling ^a   Suadicani, Sylvia O ^a   Schuster, Victor L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Eicosanoids; G protein coupled receptors; prostaglandins; signal transduction; SLCO2A1

Indexed keywords

BRADYKININ; CYCLIC AMP; MESSENGER RNA; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN TRANSPORTER;

ARTICLE; BIOAVAILABILITY; CALCIUM SIGNALING; CAMP SIGNALING; CELL MEMBRANE; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; EC50; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCINTILLATION COUNTING; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84938558801     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.51     Document Type: Article

References (55)

1. Amendt K (2005). PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis. Angiology 56: 409–415.
2. Ashby B (1998). Co-expression of prostaglandin receptors with opposite effects: a model for homeostatic control of autocrine and paracrine signaling. Biochem Pharmacol 55: 239–246.
3. Bao Y, Pucci ML, Chan BS, Lu R, Ito S, Schuster VL (2002). Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. Am J Physiol Renal Physiol 282: F1103–F1110.
4. Busch J, Frank V, Bachmann N, Otsuka A, Oji V, Metze D, et al. (2012). Mutations in the prostaglandin transporter SLCO2A1 cause primary hypertrophic osteoarthropathy with digital clubbing. J Invest Dermatol 132: 2473–2476.
5. Cattral MS, Altraif I, Greig PD, Blendis L, Levy GA (1994). Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease. Am J Med 97: 369–373.
6. Chang HY, Locker J, Lu R, Schuster VL (2010). Failure of postnatal ductus arteriosus closure in prostaglandin transporter-deficient mice. Circulation 121: 529–536.
7. Chi Y, Khersonsky SM, Chang YT, Schuster VL (2006). Identification of a new class of prostaglandin transporter inhibitors and characterization of their biological effects on prostaglandin E2 transport. J Pharmacol Exp Ther 316: 1346–1350.
8. Chi Y, Min J, Jasmin JF, Lisanti MP, Chang YT, Schuster VL (2011) Development of a high affinity inhibitor of the prostaglandin transporter PGT. J Pharmacol Exp Ther 339:633–641.
9. Civelli O (2005). GPCR deorphanizations: the novel, the known and the unexpected transmitters. Trends Pharmacol Sci 26: 15–19.
10. Dahlin A, Royall J, Hohmann JG, Wang J (2009). Expression profiling of the solute carrier gene family in the mouse brain. J Pharmacol Exp Ther 329: 558–570.
11. Diggle CP, Parry DA, Logan CV, Laissue P, Rivera C, Restrepo CM, et al. (2012). Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. Hum Mutat 33: 1175–1181.
12. Drvaric DM, Parks WJ, Wyly JB, Dooley KJ, Plauth Jr WH, Schmitt EW (1989). Prostaglandin-induced hyperostosis. A case report. Clin Orthop Relat Res 246:300–304.
13. Endo S, Nomura T, Chan BS, Lu R, Pucci ML, Bao Y, et al. (2002). Expression of PGT in MDCK cell monolayers: polarized apical localization and induction of active PG transport. Am J Physiol Renal Physiol 282: F618–F622.
14. Gether U, Andersen PH, Larsson OM, Schousboe A (2006). Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 27: 375–383.
15. Gomberg-Maitland M, Olschewski H (2008). Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 31: 891–901.
16. Gordon GR, Choi HB, Rungta RL, Ellis-Davies GC, MacVicar BA (2008). Brain metabolism dictates the polarity of astrocyte control over arterioles. Nature 456: 745–749.
17. Greengard P (2001). The neurobiology of slow synaptic transmission. Science 294: 1024–1030.
18. Henry PJ, D'Aprile A, Self G, Hong T, Mann TS (2005). Inhibitors of prostaglandin transport and metabolism augment protease-activated receptor-2-mediated increases in prostaglandin E2 levels and smooth muscle relaxation in mouse isolated trachea. J Pharmacol Exp Ther 314: 995–1001.
19. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL (1995). Identification and characterization of a prostaglandin transporter. Science 268: 866–869.
20. Kramarenko II, Bunni MA, Morinelli TA, Raymond JR, Garnovskaya MN (2009). Identification of functional bradykinin B(2) receptors endogenously expressed in HEK293 cells. Biochem Pharmacol 77: 269–276.
21. Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ, et al. (2011). SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev 63: 585–640.
22. Kudo I, Murakami M (2002). Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 68–69: 3–58.
23. Lee J, McCracken JA, Banu SK, Arosh JA (2013). Intrauterine inhibition of prostaglandin transporter protein blocks release of luteolytic PGF2alpha pulses without suppressing endometrial expression of estradiol or oxytocin receptor in ruminants. Biol Reprod 89: 27.
24. Lefkowitz RJ (1993). G protein-coupled receptor kinases. Cell 74: 409–412.
25. Letts M, Pang E, Simons J (1994). Prostaglandin-induced neonatal periostitis. J Pediatr Orthop 14: 809–813.
26. Mann JJ (2005). The medical management of depression. N Engl J Med 353: 1819–1834.
27. Miller SB (2006). Prostaglandins in health and disease: an overview. Semin Arthritis Rheum 36: 37–49.
28. Murakami M, Kudo I (2004). Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res 43: 3–35.
29. Narumiya S, Sugimoto Y, Ushikubi F (1999). Prostanoid receptors: structures, properties, and functions. Physiol Rev 79: 1193–1226.
30. Negishi M, Sugimoto Y, Irie A, Narumiya S, Ichikawa A (1993). Two isoforms of prostaglandin E receptor EP3 subtype. Different COOH-terminal domains determine sensitivity to agonist-induced desensitization. J Biol Chem 268: 9517–9521.
31. Neuschafer-Rube F, Hermosilla R, Rehwald M, Ronnstrand L, Schulein R, Wernstedt C, et al. (2004). Identification of a Ser/Thr cluster in the C-terminal domain of the human prostaglandin receptor EP4 that is essential for agonist-induced beta-arrestin1 recruitment but differs from the apparent principal phosphorylation site. Biochem J 379: 573–585.
32. Nishigaki N, Negishi M, Ichikawa A (1996). Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol Pharmacol 50: 1031–1037.
33. Nomura T, Lu R, Pucci ML, Schuster VL (2004). The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol Pharmacol 65: 973–978.
34. Nomura T, Chang HY, Lu R, Hankin J, Murphy RC, Schuster VL (2005). Prostaglandin signaling in the renal collecting duct: release, reuptake, and oxidation in the same cell. J Biol Chem 280: 28424–28429.
35. Oh DY, Kim K, Kwon HB, Seong JY (2006). Cellular and molecular biology of orphan G protein-coupled receptors. Int Rev Cytol 252: 163–218.
36. Peti-Peterdi J, Komlosi P, Fuson AL, Guan Y, Schneider A, Qi Z, et al. (2003). Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. J Clin Invest 112: 76–82.
37. Reese J, Paria BC, Brown N, Zhao X, Morrow JD, Dey SK (2000). Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse. Proc Natl Acad Sci USA 97: 9759–9764.
38. Ringel RE, Brenner JI, Haney PJ, Burns JE, Moulton AL, Berman MA (1982). Prostaglandin-induced periostitis: a complication of long-term PGE1 infusion in an infant with congenital heart disease. Radiology 142: 657–658.
39. Saadat S, Sendtner M, Rohrer H (1989). Ciliary neurotrophic factor induces cholinergic differentiation of rat sympathetic neurons in culture. J Cell Biol 108: 1807–1816.
40. Sasaki T, Niizeki H, Shimizu A, Shiohama A, Hirakiyama A, Okuyama T, et al. (2012). Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype-genotype correlation in Japanese patients with pachydermoperiostosis. J Dermatol Sci 68: 36–44.
41. Schlessinger A, Matsson P, Shima JE, Pieper U, Yee SW, Kelly L, et al. (2010). Comparison of human solute carriers. Protein Sci 19: 412–428.
42. Seifert W, Kuhnisch J, Tuysuz B, Specker C, Brouwers A, Horn D (2012). Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing. Hum Mutat 33: 660–664.
43. Smith WL, DeWitt DL, Garavito RM (2000). Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145–182.
44. Stichtenoth DO, Thoren S, Bian H, Peters-Golden M, Jakobsson PJ, Crofford LJ (2001). Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol 167: 469–474.
45. Stjernschantz J (2004). Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment. Exp Eye Res 78: 759–766.
46. 2+ signals generated by P2Y receptor activation. Glia 48: 217–229.
47. 2+ signaling. J Neurosci 26: 1378–1385.
48. Subbaramaiah K, Hudis CA, Dannenberg AJ (2011). The prostaglandin transporter regulates adipogenesis and aromatase transcription. Cancer Prev Res (Phila) 4: 194–206.
49. Sugimoto Y, Narumiya S (2007). Prostaglandin E receptors. J Biol Chem 282: 11613–11617.
50. Syeda MM, Jing X, Mirza RH, Yu H, Sellers RS, Chi Y (2012). Prostaglandin transporter modulates wound healing in diabetes by regulating prostaglandin-induced angiogenesis. Am J Pathol 181: 334–346.
51. Tai HH, Ensor CM, Tong M, Zhou H, Yan F (2002). Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 68–69: 483–493.
52. Ueda K, Saito A, Nakano H, Aoshima M, Yokota M, Muraoka R, et al. (1980). Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease. J Pediatr 97: 834–836.
53. Vezza R, Rokach J, Fitzgerald GF (2001). Prostaglandin F2alpha receptor-dependent regulation of prostaglandin transport. Mol Pharmacol 59: 1506–1513.
54. Zapata A, Kivell B, Han Y, Javitch JA, Bolan EA, Kuraguntla D, et al. (2007). Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J Biol Chem 282: 35842–35854.
55. Zhang Z, Xia W, He J, Ke Y, Yue H, Wang C, et al. (2012). Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy. Am J Hum Genet 90: 125–132.